Brief Summary
The purpose of this study is to characterize safety and to determine the recommended phase 2 regimen (RP2R) for JNJ-87801493 in combination with T-cell engagers (TCEs) [Part A: Dosethe amount of medication taken Escalation] and to further assess the safety of JNJ-87801493 at the RP2R in combination with TCEs [Part B: Dose Expansion].
Intervention / Treatment
- Drug: JNJ-87801493
- Drug: JNJ-80948543
- Drug: JNJ-75348780
Inclusion Criteria:
- Histologic documentation of B-cell NHL. All participants in part 1 must have relapsed or refractory disease with no other approved therapies available that would be more appropriate in the investigator’s judgment. In Part 2, participants with diffuse large B-cell lymphomacancers of the lymphatic system (DLBCL) or other high-grade B cell lymphoma and participants with transformed lymphoma from low-grade B cell malignancies who relapsed or failed to respond to only one prior systemic treatment regimen can be included
- Part 1 participants must have evaluable or measurable disease and Part 2 participants must have measurable disease; all as defined by the Lugano criteria for non-Hodgkin lymphoid malignancies (NHL) and the international workshop on Waldenstrom’s Macroglobulinemia (IWWM-6) for WM
- Have an Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of 0 to 2
- Hematologic laboratory parameters must meet the required criterias and the values must be without a transfusion or growth factors for at least 7 days prior to the first dose of study drug
- Participants of childbearing potential must have a negative highly sensitive serum pregnancy test (beta (β)-human chorionic gonadotropin) at screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study.